Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Yao, Xiaosai  [Clear All Filters]
2023
Chen J, Zuo Z, Gao Y, Yao X, Guan P, Wang Y, Li Z, Liu Z, Hong JHan, Deng P, et al. Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide. Clin Epigenetics. 2023;15(1):19.
Hong JHan, Yong CHan, Heng HLee, Chan JYongsheng, Lau MChan, Chen J, Lee JYi, Lim AHerbert, Li Z, Guan P, et al. Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies. Gut. 2023.
2022
Deng P, Wang Z, Chen J, Liu S, Yao X, Liu S, Liu L, Yu Z, Huang Y, Xiong Z, et al. RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancer. J Clin Invest. 2022.
2021
Liu S, Zou Q, Chen J-P, Yao X, Guan P, Liang W, Deng P, Lai X, Yin J, Chen J, et al. Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer. J Clin Invest. 2021.
2020
Xing M, Ooi WFong, Tan J, Qamra A, Lee P-H, Li Z, Xu C, Padmanabhan N, Lim JQuan, Guo YAmanda, et al. Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer. J Clin Invest. 2020.
2019
Ooi WFong, Nargund AM, Lim KJunliang, Zhang S, Xing M, Mandoli A, Lim JQuan, Ho SWei Ting, Guo Y, Yao X, et al. Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent and enhancer hijacking in primary gastric adenocarcinoma. Gut. 2019.